Drug General Information (ID: DDIQUDSLFT)
Drug Name			Tranexamic acid		Drug Info		Norgestrel		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antifibrinolytic Agents				Contraceptive Agents
Structure

Mechanism of Tranexamic acid-Norgestrel Interaction (Severity Level: Major)
Additive thrombogenic effects Click to Show/Hide Mechanism Graph
Drug Name		Tranexamic acid				Norgestrel
Mechanism		Thrombogenic effects				Thrombogenic effects
Key Mechanism Factor 1
		Factor Name		Thrombogenic effects
		Factor Description		Drug-induced thrombosis disrupts the balance between thrombogenic factors and protective mechanisms and tends to produce thrombosis. Drug-induced thrombosis usually causes venous thrombotic events, and arterial thrombotic events are also noted as a result of drug administration
Mechanism Description		Additive thrombogenic effects by the combination of Tranexamic acid and Norgestrel

Recommended Action
Management		Due to the potential for increased risk of thrombosis in women receiving hormonal contraceptives, the use of tranexamic acid for the treatment of menorrhagia in this population is considered contraindicated. Patients receiving hormonal contraceptives should be advised to seek medical attention immediately if they experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, hemoptysis, hematuria, sudden loss of vision, and pain, redness or swelling in an extremity.

References
1	Product Information. LYSTEDA (tranexamic acid). Xanodyne Pharmaceuticals Inc, Newport, KY.
2	van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR "The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study." BMJ 339 (2009): b2921.[PMID: 19679614]
3	Lidegaard O, Lokkegaard E, Svendsen AL, Agger C "Hormonal contraception and risk of venous thromboembolism: national follow-up study." BMJ 339 (2009): b2890.[PMID: 19679613]